Accord Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Accord BioPharma is a private, commercial-stage biopharmaceutical company specializing in biosimilars and generic specialty products, primarily in oncology and immunology. The company has successfully gained FDA approvals for key biosimilars like FILKRI (filgrastim) and HERCESSI (trastuzumab) and has secured formulary placements with major pharmacy benefit managers. Its strategy centers on enhancing patient access through affordable therapies and comprehensive support services, positioning it as a growing player in the competitive biosimilars market.

OncologyImmunologyCritical Care

Technology Platform

Integrated development and commercial platform for biosimilars and complex generics, focusing on analytical characterization, regulatory pathways, and patient support services.

Opportunities

The company is positioned to capitalize on the expanding U.S.

biosimilars market, driven by patent expiries of major biologics and policy support for cost-saving alternatives.

Securing preferred formulary status with major PBMs like Express Scripts provides a direct pathway for significant product uptake and market share.

Risk Factors

Intense competition from other biosimilar manufacturers leads to rapid price erosion and margin pressure.

The business is also exposed to patent litigation from originator companies, which can delay launches, and to the commercial risk of failing to secure and maintain favorable contracts with key distributors and payers.

Competitive Landscape

Accord operates in the highly competitive biosimilar and generic specialty pharmaceuticals sector, competing against large, established players like Sandoz (Novartis), Viatris, Coherus BioSciences, and Amgen, as well as other agile biosimilar-focused companies. Differentiation relies on pricing, reliable supply, formulary access, and patient support services.

More companies in Biologics / Biosimilars →More companies in United States →